{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001563577","name":"Galera Therapeutics, Inc.","summary":"Galera Therapeutics, Inc. is a biopharmaceutical company that, following the October 2025 sale of its SOD mimetics assets to Biossil, Inc., has shifted focus to developing a pan-nitric oxide synthase (NOS) inhibitor, tilarginine (L-NMMA), for treating metaplastic breast cancer (MpBC) and triple-negative breast cancer (TNBC). Its lead program is a Phase 1/2 investigator-sponsored trial at Houston Methodist in combination with nab-paclitaxel and alpelisib, funded by an NIH grant.","people":[],"products":[{"name":"Tilarginine (L-NMMA)","type":"platform","description":"Pan-NOS inhibitor in Phase 1/2 trial for metaplastic breast cancer (MpBC) and triple-negative breast cancer (TNBC), used in combination with nab-paclitaxel and alpelisib."},{"name":"Avasopasem","type":"platform","description":"SOD mimetic previously developed to reduce severe oral mucositis from radiotherapy; sold to Biossil, Inc. in October 2025."},{"name":"Rucosopasem","type":"platform","description":"SOD mimetic previously in development for radiotherapy side effects; sold to Biossil, Inc. in October 2025."}],"partnerships":[{"partner_name":"Houston Methodist","partnership_type":"licensing","description":"Nova (Galera subsidiary) holds exclusive worldwide license to Houston Methodist patents related to tilarginine for oncology use.","start_date":null},{"partner_name":"Blackstone Life Sciences","partnership_type":"strategic","description":"Royalty Agreement providing up to $80M in exchange for royalties on dismutase mimetics; rights assigned to Biossil in October 2025.","start_date":null},{"partner_name":"Biossil, Inc.","partnership_type":"strategic","description":"Galera sold avasopasem, rucosopasem, and all dismutase mimetics assets to Biossil for $3.5M upfront plus milestone payments and CVRs up to $105M.","start_date":null},{"partner_name":"I-SPY 2 consortium","partnership_type":"development","description":"Planned collaboration for a second trial of tilarginine in TNBC, contingent on securing additional capital.","start_date":null},{"partner_name":"Ikarian Capital","partnership_type":"strategic","description":"Led a syndicate investing $2.9M in Galera common stock and pre-funded warrants in support of the Nova acquisition.","start_date":null},{"partner_name":"Patheon Manufacturing Services LLC","partnership_type":"strategic","description":"Former CMO agreement for avasopasem production; agreement assumed by Biossil following asset sale.","start_date":null}],"affiliations":[],"origin":{"leaf":"71def17a86b80fc884d946f952877ff351e844cc78d770a20cfe5a31ba74b9d0","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"65bcdf79cc3f662d42197032353a71638e2aa7cd67c109cdc6079211ae61691b","parent":"b9cd63a690fb79580d62364fe25b15232c5a9b13c22e482376cc66f1b54d87a0","source":"0001563577-26-000005","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}